• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Epizyme

edit

Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors.

Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.

Milestones

edit

• 
  Epizyme received $4M in Unattributed funding. (10/14/11)
  Posted 10/14/11 at 7:04pm via epizyme.com
• 
  Epizyme received $7.5M in Unattributed funding. (6/23/11)
  Posted 6/23/11 at 8:40pm via masshightech.com
• 
  Epizyme received $8M in Series B funding. (12/8/09)
  Posted 12/8/09 at 12:45pm via fiercebiotech.com
• 
  Epizyme received $32M in Series B funding. (10/7/09)
  Posted 10/7/09 at 2:46pm via fiercebiotech.com
• 
  Epizyme — Epizyme snags $206M epigenetics deal with Eisai (3/10/11)
  Posted 3/10/11 at 7:38pm via fiercebiotech.com
• 
  Epizyme — has entered into a cancer therapeutics development and commercialization alliance with GlaxoSmithKline worth potentially more than $630 million in milestone payments (1/10/11)
  Posted 1/11/11 at 3:33am via masshightech.com
• 
  Epizyme — received $1 million research award from the Multiple Myeloma Research Foundation (1/7/11)
  Posted 1/10/11 at 6:56am via masshightech.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 12/9/09

Sources

1. Epizyme pulls in $32M in VC capital, new investors (fiercebiotech.com) [edit]
2. Epizyme amps up Series B to $40M (fiercebiotech.com) [edit]
3. Epizyme to land $7.5M from Leukemia & Lymphoma Society (masshightech.com) [edit]
4. Epizyme Achieves $4 Million in Pre-Clinical Milestone Payments in GlaxoSmithKline Alliance to Discover and Develop Novel HMT Therapeutics (epizyme.com) [edit]
5. Three Mass. biotechs get $1M from myeloma foundation (masshightech.com) [edit]
6. Epizyme enters lucrative GSK alliance (masshightech.com) [edit]
7. Epizyme snags $206M epigenetics deal with Eisai (fiercebiotech.com) [edit]